Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yahoo closed their message board. wonder why?
Got the Ole settlement from the class action. Not joining it because of future litigation I'd like to be part of that one. Not some measly million dollar settlement.
Re: Private placement and clinical trial
https://thedalesreport.com/interviews/braxia-scientific-kicks-off-clinical-trial-lands-3-million-private-placement/
Ridiculous the bounce on this then back down —
Seems coordinated
Fingers crossed! Good luck.
Let’s hope brother — we bounced here a few days ago. A lot of stocks have bounced and are in this same position.
I will put another $1K in and I'm done. Hoping for the best!
Got 7000 shares, another 7000 then I'm full until we double this price.
$3200 investment down to $668 --- Ill throw in 1k for now, and 2k when we break above .14 - after that, I am done. Would love to see .40 on t his.
__________________________________________________________________
More specifically, the Company infrastructure has:
Established access to a high-quality source of psilocybin that meets all regulatory requirements for human use in clinical research
Highlights of BRAXF
Received more than 150 referrals to date for psilocybin-assisted therapy for treatment resistant depression at our clinic in the first six weeks of opening recruitment
Received Health Canada and Research Ethics approval for protocols to collect treatment outcome data to allow for further optimization of psilocybin treatment protocols and development of best practice guidelines
Trained medical and research staff as part of Braxia Institute to provide psilocybin-assisted therapy with high quality safety monitoring. This program includes twenty (20) therapists licensed to practice in Ontario with specialized training in psilocybin-assisted therapy. All therapists were trained by the Braxia Institute and are serving as study therapists for the active psilocybin clinical trial. b
Developed physical space to safely provide psilocybin treatment with a comfortable living room-like environment with appropriate medical and psychological monitoring and protocols
Braxia Scientific Featured in National News, W5 Canada's Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses
https://finance.yahoo.com/news/braxia-scientific-featured-national-news-220000432.html
Still dont get it, we aint into shrooms yet? I was hoping this was similar gains like weed. derp derp.
I don’t get it. My friends and I all use shrooms— haha.
You can say that again! Wow!
Man, this is eating massive amounts of shit.
I have had my eye on this company. Great chart, volume ended at 1.37 mil today and the average volume is usually 723,000. CEO is doing some great research on providing patients with mental illness access to impactful treatments.
SHRMF changed to BRAXF:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
SHRMF - Have MMs OTCX & INTL been manipulating the prices here for a long time?
Anyone reported them to the SEC with screenshots yet?
Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children
We Got News!
Cheer up buddy :)
https://finance.yahoo.com/news/braxia-scientific-opens-first-ketamine-110500531.html
Dude — none ya’ll were here for so long... where the heck you been? I needing some cheering up when this thing ate shit after I bought
Mine is still showing in Schwab but I can't trade it. I guess they need to change the F tickee in the OTC for it to trade again. Probably gonna be BRAXF is my guess. Or maybe they'll just uplist to NASDAQ LOL. Wouldn't that be nice!
Appreciate that. Same with Ameriprise btw. I see SHRMF is now Braxia but neither show up in either platform so we’ll see. I’m sure it’ll be straightened out tomorrow. tx again
I guess I'll give TDA a call tomorrow if not changes by then. I'll keep you informed.
Same here, still looking
Is anyone else's account missing their SHRMF position?? Mine is not there as of the change today. TIA!
SHRMF: effective May 5,2021 Champignon Brands Inc. will change to Braxia Scientific Corp.:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Remember fellas .30-.40 is where we buy. Bid sit and wait for fills. Patience pays.
Lmfao. MMs are fuked.Our group has accumulated little over a $1millions worth. And still bidding. Come on clowns will take all those naked shorts off your hands.
Hope u all took your profits and are back on the bid to pick up more with house money.
Get some fellas. MMs ridiculous short and only a few million available at the DTC
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
662
|
Created
|
03/02/20
|
Type
|
Free
|
Moderators |
Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.
That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.
Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.
Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.
Canada NewsWire
VANCOUVER, BC, Oct. 29, 2020
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.
The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order.
Continuous Disclosure Review History
On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.
In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.
The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.
Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.
On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").
The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order.
For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time. The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.
Dr. Roger McIntyre
Chief Executive Officer
E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line: +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |